Hana Pharm Co., Ltd announces an Equity Buyback for KRW 1,000 million worth of its shares.
August 19, 2019 at 01:22 pm IST
Share
Hana Pharm Co., Ltd (KOSE:A293480) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million pursuant to a trust contract with Mirae Asset Daewoo Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on February 18, 2020. As of August 18, 2019, the company had 428,189 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase.
HANA PHARM CO., LTD is a Korea-based company mainly engaged in the manufacturing and distribution of specialty pharmaceuticals. The companyâs main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The Company also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.